Open Access
VIEWPOINT
The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma
Department of Biology, Jacksonville State University, Jacksonville, AL 36265, USA
* Corresponding Author: LE SU. Email:
Oncology Research 2025, 33(5), 1001-1005. https://doi.org/10.32604/or.2025.060573
Received 05 November 2024; Accepted 03 January 2025; Issue published 18 April 2025
Abstract
Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX. The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma, and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma, but emerging evidence suggests that upon depletion of SS18-SSX, an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival. In this article, we discuss the controversial roles of SS18-SSX’s transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of synovial sarcoma cells to SS18-SSX targeted therapeutics.Graphic Abstract

Keywords
Cite This Article

This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.